This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Anti-Aggregative Therapy and Laser Iridectomy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2007 by Sheba Medical Center.
Recruitment status was:  Recruiting
Information provided by:
Sheba Medical Center Identifier:
First received: October 25, 2006
Last updated: January 23, 2007
Last verified: January 2007
Our study investigates the effect of anti-aggregative treatment on success and complications of laser iridectomy. The study includes patients scheduled for laser iridectomy due to narrow angles.Patients will undergo first laser treatment with the anti-aggregative treatment and will scheduled for next lase in the other eye after discontinuing the anti-aggregative treatment. The patients will be followed-up for 3 months.

Condition Intervention Phase
Eyes With Narrow Angle Drug: The cessation of anti-aggregative treatment for 10 days Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Further study details as provided by Sheba Medical Center:

Study Start Date: March 2006

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients with narrow angle that need laser iridectomy and take anti- aggregative treatment
  • over 20 years old
  • patients who can stop their anti-aggregative treatment for 10 days

Exclusion Criteria:

  • under coumadin treatment
  • post ocular surgeries
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00426400

Contact: Hani Levkovitch-Verbin, MD Hani.Verbin@

Goldschleger Eye Institute Recruiting
Tel-Hashomer, Israel
Contact: Hani Levkovitch-Verbin, MD   
Principal Investigator: Hani Levkovitch-Verbin, MD         
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Hani Levkovitch-Verbin, MD Goldscheleger Eye Institute, Sheba Medical Center
  More Information Identifier: NCT00426400     History of Changes
Other Study ID Numbers: SHEBA-05-3876-HLV-CTIL
Study First Received: October 25, 2006
Last Updated: January 23, 2007 processed this record on September 19, 2017